期刊
MOLECULAR CANCER RESEARCH
卷 7, 期 12, 页码 1954-1961出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-09-0304
关键词
-
资金
- Lotus Scholars Program [200734]
- Flight Attendant Medical Research Institute Clinical Innovator
- Stop Children Cancer. Inc.
- National Cancer Institute
- NIH [R01 CA112183]
- HHMI Science for Life Undergraduate
- NATIONAL CANCER INSTITUTE [R01CA136534, R01CA112183] Funding Source: NIH RePORTER
Lung cancer has a strong etiologic association with cigarette smoking. Nicotine, a major component in tobacco smoke, functions as a survival agonist that inhibits apoptosis following various stresses. However, the mechanism of action remains elusive. Mcl-1, a major antiapoptotic protein of the Bcl2 family, is extensively expressed in both small cell and non-small cell lung cancer cells, suggesting that Mcl-1 may be a therapeutic target of patients with lung cancer. Here, we found that nicotine induces Mcl-1 phosphorylation through activation of extracellular signal-regulated kinase 1/2 in association with increased chemoresistance of human lung cancer cells. Since nicotine stimulates Mcl-1 phosphorylation and survival in cells expressing wild-type but has no such effects in cells expressing T163A Mcl-1 mutant, this indicates that nicotine induces Mcl-1 phosphorylation exclusively at the T163 site and that phosphorylation of Mcl-1 at T163 is required for nicotine-induced survival. Mechanistically, nicotine-induced Mcl-1 phosphorylation significantly enhances the half-life of Mcl-1, which renders Mcl-1 a long-term survival activity. Specific depletion of Mcl-1 by RNA interference blocks nicotine-stimulated survival and enhances apoptotic cell death. Thus, nicotine-enhanced survival of lung cancer cells may occur through activation of Mcl-1 by phosphorylation at T163 site, which may contribute to development of human lung cancer and/or chemoresistance. (Mol Cancer Res 2009;7(12):1954-61)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据